药械

订阅

MedSci主页 / 所有栏目 / 药械

4种抗凝血药物，你不可不知！

2016-09-13 李沐梓 医学界神经病学频道

抗凝血药物
关注

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632282, encodeId=706e1632282c7, content=<a href='/topic/show?id=2d0b5524e5b' target=_blank style='color:#2F92EE;'>#抗凝血药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55247, encryptionId=2d0b5524e5b, topicName=抗凝血药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b78521885856, createdName=bsmagic9139, createdTime=Wed Aug 09 03:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975696, encodeId=909d19e5696d3, content=<a href='/topic/show?id=a02b55246af' target=_blank style='color:#2F92EE;'>#抗凝血药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55246, encryptionId=a02b55246af, topicName=抗凝血药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Fri Mar 31 21:44:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128079, encodeId=d8751280e9a1, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:49:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127035, encodeId=00ba12e0350e, content=学习了，实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Sep 15 01:00:00 CST 2016, time=2016-09-15, status=1, ipAttribution=)]
    2017-08-09 bsmagic9139

    #抗凝血药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1632282, encodeId=706e1632282c7, content=<a href='/topic/show?id=2d0b5524e5b' target=_blank style='color:#2F92EE;'>#抗凝血药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55247, encryptionId=2d0b5524e5b, topicName=抗凝血药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b78521885856, createdName=bsmagic9139, createdTime=Wed Aug 09 03:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975696, encodeId=909d19e5696d3, content=<a href='/topic/show?id=a02b55246af' target=_blank style='color:#2F92EE;'>#抗凝血药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55246, encryptionId=a02b55246af, topicName=抗凝血药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Fri Mar 31 21:44:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128079, encodeId=d8751280e9a1, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:49:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127035, encodeId=00ba12e0350e, content=学习了，实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Sep 15 01:00:00 CST 2016, time=2016-09-15, status=1, ipAttribution=)]
    2017-03-31 gj0731

    #抗凝血药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1632282, encodeId=706e1632282c7, content=<a href='/topic/show?id=2d0b5524e5b' target=_blank style='color:#2F92EE;'>#抗凝血药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55247, encryptionId=2d0b5524e5b, topicName=抗凝血药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b78521885856, createdName=bsmagic9139, createdTime=Wed Aug 09 03:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975696, encodeId=909d19e5696d3, content=<a href='/topic/show?id=a02b55246af' target=_blank style='color:#2F92EE;'>#抗凝血药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55246, encryptionId=a02b55246af, topicName=抗凝血药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Fri Mar 31 21:44:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128079, encodeId=d8751280e9a1, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:49:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127035, encodeId=00ba12e0350e, content=学习了，实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Sep 15 01:00:00 CST 2016, time=2016-09-15, status=1, ipAttribution=)]
    2016-09-15 1dd8a7c5m95(暂无匿称)

    学习了，赞一个！！！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1632282, encodeId=706e1632282c7, content=<a href='/topic/show?id=2d0b5524e5b' target=_blank style='color:#2F92EE;'>#抗凝血药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55247, encryptionId=2d0b5524e5b, topicName=抗凝血药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b78521885856, createdName=bsmagic9139, createdTime=Wed Aug 09 03:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975696, encodeId=909d19e5696d3, content=<a href='/topic/show?id=a02b55246af' target=_blank style='color:#2F92EE;'>#抗凝血药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55246, encryptionId=a02b55246af, topicName=抗凝血药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Fri Mar 31 21:44:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128079, encodeId=d8751280e9a1, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:49:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127035, encodeId=00ba12e0350e, content=学习了，实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Sep 15 01:00:00 CST 2016, time=2016-09-15, status=1, ipAttribution=)]
    2016-09-15 明崖

    学习了，实用

    0

相关资讯

BMJ：两种抗凝血药物的胃肠道出血风险研究

抗凝血药物在全球范围内广泛用于多种疾病，包括心房颤动。达比加群和利伐沙班被用作华法林的替代药物用于心房颤动患者的卒中预防。这些要相对于华法林有着许多优点，包括降低了剂量、更少的药物相互作用以及不需要用药监测。药物上市后，有报道老年患者服用此类药物导致了严重的出血。大约25%的出血是和处方和剂量错误有关。现实中服用抗血小板凝集药物的病人比例更高。此外，和华法林相反，尚未有达比加群的特效解毒剂，并且无

勃林格殷格翰能否在抗凝血药领域 “扳回一城”?

【新闻事件】3月3日，德国勃林格殷格翰(Boehringer-Ingelheim)公司正式向美国FDA、欧洲药品管理局(EMA)和加拿大卫生部(HC)提交其抗凝血剂解毒剂- idarucizumab上市许可申请，并请求获得上述三家机构的加速审批资格。Idarucizumab是一种人源化的抗体片段，临床前和临床一期试验都已经证明其在抑制抗凝血剂达比加群酯（Dabigatran，商品名为泰毕全/P